Established in 2008, Cardialen, Inc., set out to develop an implantable defibrillator using low-electrical energy to restore normal heart rhythm and potentially avoid the negative side-effects of current therapies. 

  • For people living with Atrial Fibrillation (AF), the most common cardiac arrhythmia, current treatments have limited effectiveness and can cause serious side effects.

  • Ventricular Tachyarrhythmia (VT) and Ventricular Fibrillation (VF) sufferers must endure debilitating high-electrical energy shocks that can result in diminished heart function over time. 

The Cardialen unpinning termination (UPT) therapy is designed to deliver a sequence of low-energy pulses timed to stop abnormal heart rhythms that may provide a more gentle therapy than current options. 

CAUTION: Investigational Device. Limited by Federal (United States) law to investigational use only.